Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease

Sang Hyoung Park, Badr Al-Bawardy, Satimai Aniwan, Sunanda V. Kane, Nayantara Coelho-Prabhu, Konstantinos A. Papadakis, John B. Kisiel, David H. Bruining, William A. Faubion, Laura E. Raffals, Darrell S. Pardi, William J. Tremaine, Michael C. Stephens, Jeanne Tung, Sahil Khanna, Maria Alice V. Willrich, Edward V. Loftus

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background and Aims: We aimed to evaluate the relationship of serum adalimumab trough levels (ATL) with disease activity of inflammatory bowel disease (IBD) patients in a large, well-characterized referral center-based cohort. Methods: We compared serum ATL between those with clinical, biochemical, or endoscopic/radiologic disease activity and those without. Results: A total of 236 patients with IBD were included. Higher cutoff levels were associated with endoscopic and/or radiologic responses (cutoff value: 5.3 mcg/mL, P = 0.003) compared with improvement in C-reactive protein (cutoff value: 4.3 mcg/mL, P = 0.031). Conclusions: Higher cutoff ATL was associated with endoscopic and/or radiologic response.

Original languageEnglish (US)
JournalCrohn's and Colitis 360
Volume1
Issue number3
DOIs
StatePublished - Oct 1 2019

Keywords

  • Adalimumab
  • Inflammatory bowel disease
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this